

# RayBio<sup>®</sup> COVID-19 Spike-NRP1 Binding Assay Kit I

For screening COVID-19 drugs and antibodies targeting  
the Spike-Neuropilin1 protein interaction

Catalog Numbers:    CoV-NRP1S1-1 (1 plate kit)  
                              CoV-NRP1S1-2 (2 plate kit)  
                              CoV-NRP1S1-5 (5 plate kit)

User Manual  
Version 1.1

Last revised: August 12, 2021



ISO 13485:2016

3607 Parkway Lane, Suite 100  
Norcross, GA 30092

Tel: 1-888-494-8555 (Toll Free) or 770-729-2992, Fax: 770-206-2393

Web: [www.RayBiotech.com](http://www.RayBiotech.com); Email: [info@raybiotech.com](mailto:info@raybiotech.com)



RayBiotech, Inc.

---

## RayBio COVID-19 Spike-NRP1 Binding Assay Kit I Protocol

### TABLE OF CONTENTS

I.	Introduction .....	3
II.	Storage.....	5
III.	Materials Provided.....	5
IV.	Additional Materials Required .....	6
V.	Reagent Preparation .....	6
VI.	Test Reagent Sample Preparation .....	7
VII.	Assay Procedure .....	9
VIII.	Assay Procedure Summary .....	10
IX.	Data Analysis .....	10
X.	Troubleshooting Guide .....	11

## I. INTRODUCTION

The coronavirus disease 2019 (COVID-19) is caused by the SARS-CoV-2 virus. A critical step of infection is when the virus enters human host cells, which is enabled by the interaction between the SARS-CoV-2 Spike (S) protein's receptor binding domain (RBD) on the surface of the viral particle and the Angiotensin I Converting Enzyme 2 (ACE2) receptor on the surface of human cells. Recently, another human receptor, Neuropilin1 (NRP1), was shown to assist in viral entry by binding to the S-protein's CendR (C-end rule) motif, which is at the C-terminus of the S protein's subunit 1 (S1) domain. Thus, the identification of small molecules, antibodies, or other biological molecules that interfere with the formation of the S-NRP1 complex could help the development of drugs to prevent or treat COVID-19. Thus, the S-NRP1 complex represents a potential target for COVID-19 therapies and vaccines.


The RayBio® COVID-19 Spike-NRP1 binding assay kit I is a rapid, simple, and sensitive method to characterize the binding affinity of the S-NRP1 complex in the presence of potential inhibitors within 4 hours. Various inhibitor types can be tested, including small molecules, peptides, antibodies, or patient sera, for neutralizing activity against SARS-CoV-2. Using this approach, inhibitors can be screened in a high throughput fashion, accelerating the development of therapeutic drugs and vaccines to treat and prevent COVID-19.

The RayBio COVID-19 Spike-NRP1 Binding Assay Kit I contains a 96-well plate coated with recombinant NRP1. The researcher's potential inhibitor is then added to the wells in the presence of recombinant Spike S1 protein. Unbound S1 is removed with a wash step, and a mouse anti-S1 IgG detection antibody is added, binding to the S-NRP1 complex. After washing, an HRP-conjugated anti-mouse secondary IgG is then applied to the wells in the presence of 3,3',5,5'-tetramethylbenzidine (TMB) substrate. The HRP reacts with the TMB solution, producing a blue color that is proportional to the amount of bound S1. The HRP-TMB reaction is halted with the addition of the Stop Solution, resulting in a blue-to-yellow color change. The intensity of the yellow color is then measured at 450 nm.

## References

1. Ludovico Cantuti-Castelvetri, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. *Science*. 370, 856–860 (2020).
2. James L. Daly, et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. *Science*. 370, 861-865 (2020).

**Note:** RayBiotech also offers Spike-ACE2 Binding Assay Kits (cat no. CoV-SACE2, CoV-ACE2S2).



**A schematic showing how the RayBio® Spike-NRP1 Binding Assay Kit can measure the inhibition of the Spike S1 subunit and NRP1 in the presence of a potential inhibitor.**

## II. STORAGE

Upon receipt, the kit should be stored at 4°C/RT. Use within 6 months from the date of shipment.

## III. MATERIALS PROVIDED

COMPONENT	SIZE / DESCRIPTION	STORAGE / STABILITY AFTER PREPARATION
NRP1-coated Microplate (Item A)	96 wells (12 strips x 8 wells) coated with recombinant human NRP1 extracellular domain	1 month at 4°C*
Wash Buffer Concentrate (20x) (Item B)	25 ml of 20x concentrated solution	1 month at 4°C
5x Assay Diluent (Item E2)	15 ml of 5x concentrated buffer**	1 month at 4°C
Spike S1 Protein (Item F)	2 vials of purified recombinant SARS-CoV-2 Spike S1 Protein (1 vial is enough to assay half of the microplate)	4°C
Detection Antibody S1 (Item C-1)	2 vials of mouse anti-Spike S1 IgG antibody (1 vial is enough to assay half of the microplate)	4°C
HRP-Conjugated Anti-Mouse IgG (Item D-2)	15 µl of 1000x concentrated HRP-Conjugated Anti-Mouse IgG	4°C
TMB One-Step Substrate Reagent (Item H)	12 ml of 3,3',5,5'-tetramethylbenzidine (TMB) in buffered solution	N/A
Stop Solution (Item I)	8 ml of 0.2 M sulfuric acid	N/A

\*Return unused wells to the pouch containing desiccant pack, reseal along entire edge.

\*\*This item is used to dilute the "Test Reagent" (i.e., the potential inhibitor), Spike S1 Protein (Item F), Detection Antibody S1 (Item C-1), and HRP-Conjugated Anti-Mouse IgG (Item D-2).

#### IV. ADDITIONAL MATERIALS REQUIRED

1. Microplate reader capable of measuring absorbance at 450 nm
2. Shaker
3. Pipettes capable of accurately delivering 2  $\mu$ l to 1 ml volumes
4. Pipettes capable of delivering 1 – 25 ml volumes for reagent preparation
5. Graduated cylinders: 100 ml and 1 liter
6. Distilled or deionized water
7. Tubes to prepare “Test Reagent” sample dilutions

#### V. REAGENT PREPARATION

1. Bring all reagents and “Test Reagent” samples to room temperature (18 - 25°C) before use.
2. 5x **Assay Diluent** (Item E2) should be diluted 5-fold with deionized or distilled water before use to make a “1x Assay Diluent.”
3. If the **Wash Concentrate** (20x) (Item B) contains visible crystals, warm to room temperature and mix gently until dissolved. Dilute 25 ml of Wash Buffer Concentrate into deionized or distilled water to yield 500 ml of “1x Wash Buffer.”

***Note:** 500 ml of 1x Wash Buffer is enough to wash the plate as recommended.*

4. Briefly spin the **Spike S1 Protein** (Item F) before use. Add **100  $\mu$ l** of 1x Assay Diluent into the **S1 Protein** vial to prepare a “50x S1 Protein Concentrate”. Pipette up and down to mix gently. This protein concentrate should then be diluted 50-fold with 1x Assay Diluent to yield a “1x S1 protein” solution and will be used in Part VII, step 6. (see also Part VI, Test Reagent Sample Preparation on page 7)
5. Briefly spin the **Detection Antibody S1** (Item C-1) before use. Add 100  $\mu$ l of 1x Assay Diluent into the vial to prepare a 55x detection antibody concentrate. Pipette this detection antibody concentrate up and down to mix gently. This detection antibody concentrate should then be diluted 55-fold with 1x Assay Diluent to yield a “1x Detection Antibody” solution and will be used in Part VII, step 6.
6. Briefly spin the **HRP-Conjugated Anti-Mouse IgG** (Item D-2) before use. HRP-Conjugated Anti-Mouse IgG should be diluted 1000-fold with 1x Assay Diluent to yield a “1x HRP-conjugated IgG” solution. Each reaction requires 100 $\mu$ l of 1x HRP-conjugated IgG solution, thus, the researcher should create enough volume to perform the desired number of reactions for each experiment.

## VI. TEST REAGENT SAMPLE PREPARATION

### General Considerations

**Dose Response.** When evaluating a potential inhibitor (i.e., the Test Reagent) for its ability to block formation of the spike-NRP1 complex, it is highly recommended to perform a titration curve. This approach will help the researcher to empirically determine the dose-responsive range of Test Reagent as well as the lowest level that yields detectable inhibition. It will also help confirm whether the inhibition is real; that is, whether the inhibition increases as more Test Reagent is applied.

Since different Test Reagents will inhibit spike-NRP1 binding to different extents, there is no recommended starting dilution. Rather, it is encouraged that the researcher choose a dilution series based on their knowledge of the Test Reagent.

**Preparation of Reactions.** Since the Spike S1 protein putatively competes with the Test Reagent for binding to NRP1, it is critical that Spike S1 be present in the same concentration in every well. An example is provided below of how to prepare a Test Reagent serial dilution in which the concentration of Spike S1 is held constant while the Test Reagent varies. Note that the researcher should determine an appropriate serial dilution based on the known properties of their Test Reagent. From the result of this dilution series, the best dilution of the Test Reagent can be empirically determined.

### ***Serial Dilution Preparations.***

1. Label a series of tubes for preparation of a serial dilution of the Test Reagent. For an example of how to set up this serial dilution, refer to the Serial Dilution Example below.
2. Mix the Test Reagent with the Assay Diluent and Spike S1 Protein Concentrate (prepared on page 6 in Part V, step 4) to create the first reaction mix. NOTE: it is recommended that all Test Reagent samples be run at least in duplicate. Therefore, replicates should be taken into account when calculating the volumes to be prepared.
3. Create the remaining reaction mixes according to the dilution series set forth in step 1 of the example below, or as needed for the researchers chosen dilutions.

### SERIAL DILUTION EXAMPLE

*In this example, the Test Reagent stock solution = 100 mM, and the researcher wishes to test 20 mM, 2 mM, 0.2 mM, 0.02 mM, and 0.002 mM dilutions of the Test Reagent.*


1. Label 5 serial dilution tubes as follows: 20 mM, 2 mM, 0.2 mM, 0.02 mM, and 0.002 mM.
2. Make the first reaction mix:
  - a. In the tube labeled "20 mM", prepare the first reaction mix by mixing the following components:
    - 50  $\mu$ l of the Test Reagent stock solution

- 2.5  $\mu$ l of Spike S1 Protein Concentrate (prepared on page 6 in Part V, 4)
  - 197.5  $\mu$ l 1x Assay Diluent
- b. Mix thoroughly. This creates sufficient volume to run duplicate wells.


**NOTE:** It is strongly recommended to include a vehicle control to assess effects of the Test Reagent's solvent or buffer on the Spike-NRP1 reaction. For example, if the Test Reagent is in dimethyl sulfoxide (DMSO), a parallel set of tubes should be prepared with 50  $\mu$ l of DMSO (step 2 above).

3. Make the remaining reaction mixes:

- a. The Spike S1 Protein Concentrate prepared in Part V step 4 (page 6) should be diluted 100-fold with Assay Diluent to make 1200  $\mu$ l of Spike S1 Protein Working Solution.
- b. Pipette 225  $\mu$ l of the 1x Spike S1 Protein Working Solution into the remaining four empty tubes (2 mM, 0.2 mM, 0.02 mM, 0.002 mM):



- c. Pipette 25  $\mu$ l from the first reaction mix (20 mM tube) into the second serial dilution tube (2 mM). Mix thoroughly.
- d. Repeat for each serial dilution, using 25  $\mu$ l of the prior concentration until the final concentration is reached:



- e. Finally, pipette 250  $\mu$ l of the 1x Spike S1 Protein Working Solution into a separate tube labeled "0 mM." Mix thoroughly. This reaction contains no Test Reagent and will serve as the positive control.

**NOTE:** You will need to perform this positive control sample, as well as any vehicle control samples for every individual assay performed, even after the best dilution of your Test Reagent is identified.



## VII. ASSAY PROCEDURE

1. Bring all reagents to room temperature (18 - 25°C) before use. It is recommended that all controls and Test Reagent samples be run at least in duplicate.
2. Label removable 8-well strips as appropriate for your experiment.
3. As prepared above in Part VI, **add 100 µl of each Test Reagent sample** into an appropriate well.

*Note: For data reliability, it is recommended that all Test Reagent samples should be run in at least duplicate.*

4. Cover wells with the provided plate sealing film and incubate for 2.5 hours at room temperature or overnight at 4°C with gentle shaking.
5. Discard the solution and **wash 4 times** with 1x Wash Solution. Wash by filling each well with 1x Wash Buffer (300 µl) using a multi-channel pipette or auto-washer. Complete removal of liquid at each step is essential for good performance. After the last wash, remove any remaining 1x Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
6. Add 100 µl of prepared **1x Detection Antibody** (Reagent Preparation Step 5) to each well. Incubate for 1 hour at room temperature with gentle shaking.
7. Discard the solution and repeat the wash step as described Step 5 above.
8. Add 100 µl of the prepared **1x HRP-conjugated IgG** (see Reagent Preparation Step 6) to each well. Incubate for 1 hour at room temperature with gentle shaking.
9. Discard the solution. Repeat the wash as described in Step 5 above.
10. Add 100 µl of **TMB One-Step Substrate Reagent** (Item H) to each well. Incubate for 30 minutes at room temperature in the dark with gentle shaking.
11. Add 50 µl of **Stop Solution** (Item I) to each well.
12. Read at 450 nm immediately.

## VIII. ASSAY PROCEDURE SUMMARY

1. Prepare all reagents and Test Reagent samples as instructed.
2. Add 100 µl Test Reagent samples to each well. Incubate 2.5 hours at room temperature or overnight at 4°C.
3. Add 100 µl prepared Detection Antibody to each well. Incubate 1 hour at room temperature.
4. Add 100 µl the prepared 1X HRP-conjugated IgG antibody solution. Incubate 1 hour at room temperature.
5. Add 100 µl TMB One-Step Substrate Reagent to each well. Incubate 30 minutes at room temperature.
6. Add 50 µl Stop Solution to each well. Read at 450 nm immediately.

## IX. DATA ANALYSIS

1. Determine the average absorbance across the replicate readings for each Test Reagent and positive control samples performed.
2. *Optional:* If running the recommended vehicle control as well, subtract these values from your Test Reagent values.
3. Compare the Test Reagent sample data to the positive control, 0 mM sample (no Test Reagent).

**Note:** A Test Reagent's sample absorbance will decrease if the spike-NRP1 interaction is inhibited when compared to the positive control, and that reduction can be compared directly by measuring the percent binding inhibition of the interaction against the positive control.

4. Determine the percent binding inhibition (BI%):


$$\text{BI\%} = [1 - (\text{OD of Test Reagent} / \text{OD of positive control})] \times 100$$

**Note:** This calculation uses OD's after subtraction of vehicle control.

## X. TROUBLESHOOTING GUIDE

Problem	Cause	Solution
Signal with Test Reagent is too high	Test Reagent concentration is too low	Increase Test Reagent concentration
	Test Reagent does not inhibit the Spike interaction	Use a different Test Reagent.
Large CV	Inaccurate pipetting	Check pipettes
High background	Plate is insufficiently washed	Review the manual for proper washing. If using an automated plate washer, check that all ports are unobstructed.
	Contaminated wash buffer	Make fresh wash buffer
Low "no Test Reagent sample" signal	Improper storage of kit	Upon receipt, the kit should be stored at 4°C
	Inaccurate amount of Stop Solution added. Plate not read immediately after adding Stop Solution.	Stop Solution should be added to each well. The OD should be read immediately after adding the Stop Solution.
	Improper dilution of protein, primary or secondary antibody	Ensure correct dilution

This product is for research use only.



© 2021 RayBiotech, Inc.